Skip to main content

Real World Evidence Collaboration between Karolinska Institutet and Merck and Co., Inc. to be inaugurated at MSD

Nyhet   •   Nov 16, 2016 15:55 CET

A long-term collaborative agreement has been reached between Karolinska Institutet and Merck & Co., Inc. The agreement brings a five-year collaborative commitment that will focus on utilization of real world evidence, and may also include clinical studies.

-We are very happy to be able to facilitate this collaboration and tie the knot between our CORE organization and Karolinska Institutet. This collaboration is a great example of how we can make the most of Swedish conditions and allure financial strength to Swedish Life science for the gain of patients everywhere, says Acting CEO at MSD, Ulf Janzon.

Intellectual as well as financial investment in Swedish life science

The overall goal is to address clinically important research questions and to describe patient management in order to improve patient outcomes and quality of care. This collaboration will constitute a significant intellectual knowledgebase as well as international investment to Swedish life science. During the first year the total investment will amount to 10 million SEK, decisions on investments during the rest of the collaboration period will be taken continuously by a steering group with representatives from both KI and Merck & Co., Inc.

High-level celebrations with political interest

An inauguration ceremony will be held at the MSD, the Swedish subsidiary of Merck & Co., Inc., on Monday November 21st. The ceremony will provide an opportunity to learn on reason and scope of the collaboration, as well as meeting high level scientists from both Karolinska Institutet and Merck & Co., Inc. Professor Alexander von Gabain, Deputy Vice-Chancellor for Innovation and Commercial Outreach, Karolinska Institutet, will share his view of what value the agreement will bring to research at KI and Dr. Susan Shiff, Head of Centre for Observational and Real-world Evidence (CORE), Merck & Co., Inc. will elaborate on what value the agreement will bring to R&D at Merck & Co., Inc. Dr. Anna Nilsson Vindefjärd, Secretary General of Research!Sweden will be moderating the event.

Further celebrations of the agreement will take place at the American Embassy on the morning of November 22nd when the Deputy Chief of Mission of the United States Embassy Mr. David Lindwall will elaborate on the prosperous business connections between the United States and Sweden and the great opportunities that this collaboration provides for Swedish life science.